To enhance the stability in vivo, new derivatives of cytogenin were synthesized, and their biological activity and stability in mice were estimated. 2-(8-Hydroxy-6-methoxyl -oxo-l//-2-benzopyran-3-yl)propionic acid (NM-3) was found to be the most stable among them. It modified collagen-induced arthritis in mice. It also showed potent anti-angiogenic activity in a mousedorsal air sac assay.
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Cytogenin 1 ( Fig. 1 ) was first found as an immunomodulative antitumor substance produced by Streptoverticillum eurocidiumx\ Later, it was found that cytogenin had an antiinflammatory activity against collagen-induced arthritic model in mice2'3). However, cytogenin readily transformed to the less active sulfate or glucronide, or was oxidized to the 3-carboxylic acid (MC-1) in the biological assessment in mice. These metabolic conversions seemed to reduce efficacy of cytogenin. So we prepared O-acyl and O-alkyl derivatives of cytogenin to prevent glucuronide or sulfate conjugation, and the 3-side chain modified analogues to avoid oxidation. Amongthese derivatives, NM-3(2a in Fig.   1 ) showed the best pharmacological properties.
In this paper, we report the syntheses, stability in vivo, and the pharmacological activities of the cytogenin derivatives.
Materials and Methods
O-Acyl Derivatives of Cytogenin As shown in Scheme 1, O-acyl derivatives 4-ll were prepared simply by acylation with acylating agent in the presence of base (method A), or by nucleophilic displacement of the chloride 3, which was easily prepared by chlorination of cytogenin with PPh3-CCl4, with the corresponding nucleophilic reagent (method B). In the method A, acylation generally occurs at the 9-position first, and acylation at the 8-position was slow because of the hydrogen bond with the 1-carbonyl group. In the method B, after the nucleophilic displacement, the Boc group was deprotected by TFA, if necessary. On the other hand, the 9-0-carboxymethyl derivative 16 was prepared as follows. carboxy derivative 2 was obtained by heating of the nitrile 17 in a 1 : 1 mixture of concentrated hydrochloric acid and acetic acid (Scheme 3).
C-Alkyl Derivative of 2
The preparation of C-alkyl derivatives are shown in Scheme 3. First, the 8-hydroxyl group in 17 was protected as the fer^butyldimethylsilyl ether 18. Usual alkylation procedures such as sodium hydride and alkyl halide gave the dialkyl product as a main product. So we employed the two phase system of aqueous sodium hydroxide and dichloromethane in the presence of tetrabutyl ammonium bromide as a phase transfer catalyst to obtain the monoalkyl product. Even under these conditions, the reaction should be stopped generally within an hour before the dialkyl compound become a major product. Thus, mono-alkyl compounds19a~c were prepared along with the recovery of about a half the amount of the starting material 18.
Mono alkyl nitriles 19a~c were hydrolyzed to 2a (NM-3), 2b and 2c, respectively.
Dialkyl derivatives 20a~c were obtained by using sodium hydride and alkyl halide, concomitant with partial desilylation as a side reaction. The 9,9-dimethylnitrile 20a was hydrolyzed to give the carboxylic acid 21a in 45% yield.
However, the complete hydrolysis proved more resistant on the more hindered dialkyl compounds 20b and 20c under the same or even more drastic conditions, affording only the carbamoyl compounds 21b and 21c, re spectively.
Results and Discussion

Metabolite Profile
Orally administered cytogenin was rapidly metabolized in mice and excreted in urine mainly as the 8 (or 9)-O- Table 1 . 0-acyl derivatives 4, 5, 8, 9 and 10 were unstable in a plasma and deacylated to cytogenin. Although the O-acyl derivatives having a carboxyl group such as 6 and 7 were stable in a plasma, they were deacylated in vivo to cytogenin and gave the same metabolites as in the case of cytogenin. Based on these results and from the fact that MC-1existed without conjugation, we assumed that other compounds having a carboxyl function in the molecule would be stable both in vitro and in vivo. Therefore, the stability of the carboxymethyloxy derivative 16 and carboxylic acids 2, 2a~c and 21a were examined. They showed high stability and remained largely intact both in vitro and in vivo. On the other hand, 9,9-dialkyl carboxamides 21b and 21c were unstable. These findings showed that the carboxylic acid function is crucial for the in vivo stability.
Pharmacological Activities
Anti-arthritic activities of the derivatives with good in vivo stability were evaluated using type II collagen-induced arthritic mice at a dose of 20mg/kg or 30mg/kg, p.o. The inhibitory activities are shown in Table 2 . The ED50 values of NM-3 and cytogenin were 4.4 mg/kg/day and 44 mg/kg/ day, respectively. As indicated by the data in Table 2 , the anti-arthritic activity was exhibited by only a few limited compounds, by oral administration. The -C9-COOH linkage at C-3 is essential for exhibition of the activity. Substitution at the C-9 position was effective in strengthening the activity, and the methyl group was most efficacious. The bulkier substituents such as ethyl for compound2b or dimethyl for compound21a showed less potent activity. Anti-angiogenic activity has been found for cytogenin4).
So a mouse dorsal air sac assay, as described in the previous report^, was also examined for cytogenin derivatives. As shown in Table 2 , compounds 2a (NM-3) and 21a were more active than cytogenin. NM-3showed 78% inhibitory activity against the angiogenesis induced by S-180 tumor cells in mice at a single dose of lOmg/kg,
When 25mg/kg of NM-3 was orally administered, the maximal blood concentration (Cmax) reached 129.3 /ag/ml (T1/2: 3.43hour, Tmax: 0.141 hour), which was about 100 times higher than that of cytogenin. The area under the curve (AUG) value was 777 mg à"hr/ml. Furthermore, the acute toxicity test in mice showedthat NM-3had extremely low toxicity (the LD50 value was more than 1g/kg by p.o.). Consequently, NM-3 is the most promising candidate as an orally available therapeutic agent for the treatment of angiogenesis-associated diseases and rheumatoid arthritis.
Experimental General NMRspectra were recorded on a JEOL JNM-GSX400 spectrometer. Chemical shifts are expressed in <5-value down field from TMSas an internal standard. FAB-MS spectra were measured on a JEOL JMS-SX102A spectrometer using m-nitrobenzyl alcohol as a matrix.
Silica gel column chromatography was carried out on silica gel 60 (Merck). IR and UVspectra were recorded on a JASCOFT-IR 5300 spectrophotometer and Hitachi model U-32 1 0 spectrophotometer, respectively.
Metabolites of Cytogenin
Male Sprague-Dawley rats weighing 150-160g (Japan SLC Inc, Shizuoka, Japan) were fasted overnight before and 8hours after dosing. After oral administration of cytogenin (200 mg/kg), rats were kept separately in a glass metabolism cage. Urine was collected for up to 8 hours and analyzed before and after hydrolysis with sulfatase and/or After oral administration of the compounds (25 mg/kg), mice were anesthetized with diethyl ether at 5, 15 and 30 minutes, and blood was drawn from the abdominal aorta. The plasma samples (0.2 ml) obtained by centrifugation of the blood were analyzed before and after hydrolysis with 5 mg sulfatase contains a-glucronidase (Sigma, S-9626) in 1.0ml of0.2m acetate buffer (pH 5.0 ) at 37°C for 2hours.
After adding 1.5ml of saturated ammoniumsulfate, the reaction mixture was mixed with 3 ml of ethyl acetate and centrifuged at 1700# at 4°C for 10minutes. The resultant supernatant wasevaporated in vacuo and the residue was re-dissolved with 0.2ml of 50% methanol for the HPLC analysis. The conjugation rate (%) was calculated as [(Area of the compound after deconjugation by the mixed enzymes-Area of the compound before deconjugation)/ Area of the compound after deconjugation] X 100.
HPLCAnalysis
The HPLCapparatus included two 6-AD HPLCpumps The column effluent was monitored by the ultraviolet absorption at 244 nm.
Anti-arthritic Activity
Male DBA/1J mice (Charles River Japan, Atsugi, Japan)
were used at 8-12 weeks of age for the collagen-induced arthritis experiment. The animals were housed under standard laboratory conditions and were fed food and water ad libitum. All compounds used were dissolved or suspended in physiological saline or 0.5% carboxymethylcellulose (CMC) (Wako Pure Chemical Industries, Osaka, Japan). Bovine type II collagen (Cosmo-Bio, Tokyo, Japan) was dissolved in 0.01 m acetic acid at a concentration of 2 mg/ml before use. Mice were immunized by intradermal injection at a base of the tail with lOO^g of native collagen emulsified in an equal volume of Freund's complete adjuvant (Difco Labs., Detroit, MI, USA). Three weeks later, mice were boosted by i.p. injection with 100 jig of the same emulsified native collagen. Groups of 6 to 10 mice were daily treated p.o. with the compounds at a dose of20 mg/kg/day for 3 weeks after the injection of booster.
Groups of3 and 6 to 10 mice were used for normal control (normal) and arthritis control (control), respectively.
Normal and control mice received vehicle alone in the same manner. The mice were observed for clinical arthritis and were scored by grading each paw from 0 to 4 based on erythema and swelling of the joint (0=no erythema or swelling; 1 =erythema or swelling of one toe; 2=erythema or swelling of two or more of the toe; 3=erythema and swelling of the entire paw; 4=complete erythema and swelling of the entire paw and incapacity to bend the ankle). All four legs were scored; the highest score reached 16. Inhibitory percent on arthritis was calculated as [(C-T) /C]X l00, where C was the maximal score of control group and T was that of treatment group.
Anti-angiogenic Activity Anti-angiogenic activity was evaluated using a mouse dorsal air sac assay. The assay was performed as described previously5). The compoundwas administered orally once daily (10 or lOOmg/kg) for 5 consecutive days to ICR mice (Charles River Japan). Andthe angiogenic response was assessed by determining the number of newly formed blood vessels, induced by inplanted chamber containing S-180 tumor cells.
3-Chloromethyl-8-hydroxy-6-methoxy- 8-Acetoxy-3-hydroxymethyl-6-methoxy-1 -oxo-\H-2-benzopyran (4)
A mixture of 1 (500mg, 2.25mmol), pyridine (0.24ml, 2.92mmol) and acetic anhydride (0.26ml, 2.70mmol) in THF(2ml) were stirred at room temperature for 15 hours.
The reaction mixture was diluted with water and extracted with EtOAc (50ml). The organic layer was washed with water and brine, dried over Na2SO4, and then concentrated. The residue was crystallized from methanol to give 4 (302 mg, 51% yield).
IR ( 8-Acetoxy-3-acetoxymethyl-6-methoxyl -oxo-l//-2-benzopyran (5)
Compound5 was prepared by use of a similar procedure analogous to that described for the preparation of 4 except for the amount ofreagent (Ac2O, 12 eq; pyridine, 12 eq). 
2-benzopyran (7)
By use of a procedure analogous to that described for the preparation of 6, compound 7 was prepared from 1 and glutamic anhydride (77% yield). mmol) in DMF(5ml) was stirred at 80°C for 2hours. The reaction mixture was diluted with water and extracted with EtOAc (50ml) . The organic layer was washed with water and brine, dried over Na2SO4, and then concentrated. The residue was purified by silica gel column chromatography to give iV-Boc derivative of 10 (510mg). To a solution of this compound in CH2C12 (10ml) was added TFA (l ml).
After stirring at room temperature for 10 hours, the reaction mixture was concentrated. The residue was diluted with EtOAc (50 ml), washed successively with saturated sodium bicarbonate, water and brine. The organic layer was dried over Na2SO4 and concentrated to give 10 (237mg, 55% yield 3 -(2 , 6-Diaminohexanoyloxy)methyl-8 -hydroxy-6-methoxyl -oxo-l//-2-benzopyran (1 1) By use of a procedure analogous to that described for the preparation of 10, compound ll was prepared from 1 and AyV'-di-Boc-lysine as trifluoroacetic acid salt (77% yield 3 -Hydroxymethyl-8 -carboxymethyloxy-6-methoxy-1 -oxol//-2-benzopyran (1 4) A solution of 1 (330mg, 1.50mmol), potassium carbonate (330mg, 2.25 mmol) and /-butyl bromoacetate (1.1ml, 7.50mmol) in DMF(5ml) was stirred at room temperature for 19 hours. The reaction mixture was diluted with water and extracted with EtOAc (100 ml). The organic layer was washed with water and brine, dried over Na2SO4, and then concentrated. The residue was purified by silica gel column chromatography to give /-butyl ester of 14 (501 mg). To a solution of the /-butyl ester (501 mg) in CH2C12 (5ml) was added TFA (lml). After stirring at room temperature for 2hours, the reaction mixture was concentrated. Crystallization from MeOH(5 ml) gave 14 (21l mg, 51% yield). 3 -Hydroxymethyl-6 -methoxy-8 -methoxymethyloxy-1 -oxol//-2-benzopyran (15) To a solution of3 (500mg, 2.25mmol) in. DMF.(lOml), sodium hydride (60%, in oil, 166mg, 4.15mmol) and chloromethylmethylether (0.80 ml, 1 0.24 mmol) were added at 0°C. After stirring at room temperature for 2hours, the reaction mixture was diluted with water and extracted with EtOAc(100 ml). The organic layer was washed with water and brine, dried over Na2SO4,and then concentrated. To a solution of the residue in DMF(10ml) was added sodium formate (1.40 g, 10. 3 mmol) and the solution was stirred at 80°C for 2hours. The reaction mixture was diluted with water and extracted with EtOAc (100 ml). The organic layer was washed with water and brine, dried over Na2SO4, and then concentrated. Theresidue in acetonitrile wastreated with sodium bicarbonate (10ml) at 40°C for 17hours. The reaction mixture was diluted with EtOAc(100ml), which was washed with water and brine, dried over Na2SO4and concentrated to give 15 (526 mg, 88% yield).
IR ( 3 -Carboxymethyloxymethyl-8-hydroxy-6-methoxy-1 -oxol //-2-benzopyran (1 6) To a solution of15 (300mg, 1.13mmol) in DMF(10ml), sodium hydride (136 mg, 3.40 mmol) and bromoacetic acid f-butyl ester (0.83 ml, 5.66mmol) were added at 0°C. After stirring at room temperature for 2hours, the reaction mixture was diluted with water and extracted with EtOAc (100ml). The organic layer was washed with water and brine, dried over Na2SO4, and then concentrated. After chromatographic purification, the ester was dissolved in acetonitrile (10ml) and was treated with 1 MHC1 (10ml) at 40°C for 1 hour. The reaction mixture was diluted with EtOAc (50ml), which was washed with water and brine, dried over Na2SO4,and then concentrated. To a solution of the residue in CH2C12 (5 ml) was added TEA (1 ml), and the solution was stirred at room temperature for 2hours. The reaction mixture was added water and extracted with EtOAc (50ml). The organic layer was washed with water and brine, dried over Na2SO4 and concentrated. Crystallization from EtOAc (10ml) gave 16 (140mg, 44% yield). 3-Carboxy-8-hydroxy-6-methoxyl -oxo-l/f-2-benzo-
To a solution of1 (3.6g, 16.2mmol) in acetone (100ml) was added Jones' reagent (14ml) at 0°C. After stirring at the same temperature for 10minutes, the mixture was 293 diluted with water (500 ml) and extracted with EtOAc. The organic layer was washed with 20% aq. NaCl (200mix3). The extract was back-extracted with 5%NaHCO3(300 mix4 (8-Hydroxy-6-methoxyl -oxo-17:/-2-benzopyran-3-yl)-acetic acid (2) To a solution of17 (1.50g, 6.49mmol) 8 -^-Butyldimethylsilyloxy-3 -cyanomethyl-6-methoxy-1 -oxol//-2-benzopyran (1 8) To a solution of crude 17, which was prepared from 21.6 g of 3, in DMF (200ml), imidazole (12.2g, 1.80.2mmol) and /-butyldimethylchlorosilane (21.8 g, 144.1 mmol) were added at 0°C and the solution was stirred at the same temperature for 2 hours. The reaction mixture was diluted with water and extracted with toluene (400 ml). The organic layer was washed with water and brine, dried over Na2SO4, and then concentrated. 
To a vigorously stirred solution of 18 (10.0 g, 29.0mmol) in two phase system of CH2C12 (200ml)-1 m NaOH(200 ml), tetra-w-butyl ammonium bromide (2.34 g, 7.25 mmol) and methyl iodide (7.2ml, 1 15.9mmol) were added and the solution was stirred at 0°C for 1 hour. The organic layer was separated, washed with water and brine, dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography to give 19a (4.79 g, 46% yield). 8-^-Butyldimethylsilyloxy-3 -( 1 -cyanopropyl)-6-methoxyl -oxo-l//- 2-benzopyran (19b) By use of a procedure analogous to that described for the preparation of 19a, 19b was prepared from 18 and ethyl bromide (26% yield). 8-£-Butyldimethylsilyloxy-3-( l -cyano-1 -propyl)butyl-6-methoxy-1 -oxo-l//-2-benzopyran (20b) Byuse of a procedure analogous to that described for the preparation of 20a, 20b was prepared from 18 and propyl iodide (82% yield). IR (KBr) cm"1 1735, 1600, 840; UV (MeOH) Amax nm (£) 8-f-Butyldimethylsilyloxy-3 -( 1 -benzyl-1 -cyano-2-phenyl)-ethyl-6-methoxy-1 -oxo-l//-2-benzopyran (20c) By use of a procedure analogous to that described for the
